Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
13.39
+0.84 (6.69%)
At close: Apr 20, 2026, 4:00 PM EDT
13.59
+0.20 (1.49%)
After-hours: Apr 20, 2026, 6:23 PM EDT
Artiva Biotherapeutics Employees
Artiva Biotherapeutics had 104 employees as of December 31, 2025. The number of employees increased by 15 or 16.85% compared to the previous year.
Employees
104
Change
15
Growth
16.85%
Revenue / Employee
n/a
Profits / Employee
-$806,394
Market Cap
330.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 104 | 15 | 16.85% |
| Sep 30, 2025 | 106 | 24 | 29.27% |
| Jun 30, 2025 | 105 | 23 | 28.05% |
| Mar 31, 2025 | 96 | 15 | 18.52% |
| Dec 31, 2024 | 89 | 8 | 9.88% |
| Sep 30, 2024 | 82 | - | - |
| Jun 30, 2024 | 82 | - | - |
| Mar 31, 2024 | 81 | - | - |
| Dec 31, 2021 | 43 | 21 | 95.45% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Abeona Therapeutics | 226 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Protara Therapeutics | 46 |
| Inhibikase Therapeutics | 35 |
ARTV News
- 12 days ago - Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - GlobeNewsWire
- 2 months ago - Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire